Oncobiologics (OTLK) Competitors $1.04 -0.01 (-0.48%) As of 09:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. CLYM, ACTU, NVCT, CHRS, SCLX, ELDN, ACOG, CABA, CLLS, and GLSIShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Climb Bio (CLYM), Actuate Therapeutics (ACTU), Nuvectis Pharma (NVCT), Coherus Oncology (CHRS), Scilex (SCLX), Eledon Pharmaceuticals (ELDN), Alpha Cognition (ACOG), Cabaletta Bio (CABA), Cellectis (CLLS), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry. Oncobiologics vs. Its Competitors Climb Bio Actuate Therapeutics Nuvectis Pharma Coherus Oncology Scilex Eledon Pharmaceuticals Alpha Cognition Cabaletta Bio Cellectis Greenwich LifeSciences Oncobiologics (NASDAQ:OTLK) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations. Do institutionals & insiders believe in OTLK or CLYM? 11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 4.8% of Oncobiologics shares are owned by insiders. Comparatively, 0.8% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is OTLK or CLYM more profitable? Oncobiologics' return on equity of 0.00% beat Climb Bio's return on equity.Company Net Margins Return on Equity Return on Assets OncobiologicsN/A N/A -332.30% Climb Bio N/A -23.10%-22.47% Which has better valuation and earnings, OTLK or CLYM? Climb Bio has lower revenue, but higher earnings than Oncobiologics. Climb Bio is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncobiologics$1.51M30.98-$75.37M-$0.57-1.84Climb BioN/AN/A-$73.90M-$0.70-2.91 Which has more volatility and risk, OTLK or CLYM? Oncobiologics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Do analysts recommend OTLK or CLYM? Oncobiologics presently has a consensus price target of $9.60, indicating a potential upside of 814.29%. Climb Bio has a consensus price target of $9.00, indicating a potential upside of 341.18%. Given Oncobiologics' higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than Climb Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Climb Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Does the media favor OTLK or CLYM? In the previous week, Climb Bio had 1 more articles in the media than Oncobiologics. MarketBeat recorded 3 mentions for Climb Bio and 2 mentions for Oncobiologics. Climb Bio's average media sentiment score of 1.11 beat Oncobiologics' score of 0.45 indicating that Climb Bio is being referred to more favorably in the news media. Company Overall Sentiment Oncobiologics Neutral Climb Bio Positive SummaryClimb Bio beats Oncobiologics on 8 of the 15 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOncobiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.20M$3.15B$5.80B$10.16BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-1.8421.2475.2426.40Price / Sales30.98428.49513.38175.37Price / CashN/A44.4425.8129.91Price / Book-0.349.6413.606.28Net Income-$75.37M-$53.20M$3.29B$270.38M7 Day Performance13.34%0.07%0.15%1.89%1 Month Performance-55.13%4.27%4.64%6.01%1 Year Performance-82.29%9.62%76.99%25.26% Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOncobiologics2.1423 of 5 stars$1.05-0.5%$9.60+818.7%-83.8%$46.42M$1.51M-1.8320Short Interest ↑CLYMClimb Bio3.7721 of 5 stars$2.47+3.3%$9.00+264.4%N/A$167.37MN/A-3.539Positive NewsGap UpACTUActuate Therapeutics2.5319 of 5 stars$7.94-3.6%$20.33+156.1%-12.6%$164.76MN/A0.0010NVCTNuvectis Pharma3.479 of 5 stars$6.40-4.2%$15.33+139.6%-7.2%$162.93MN/A-5.478Positive NewsCHRSCoherus Oncology4.2163 of 5 stars$1.37+6.2%$4.51+229.4%-2.3%$159.24M$266.96M0.88330SCLXScilex2.207 of 5 stars$22.17-2.8%$455.00+1,952.3%-36.1%$158.59M$44.24M-0.7680Positive NewsGap UpELDNEledon Pharmaceuticals3.034 of 5 stars$2.58-4.8%$10.00+287.6%-7.2%$154.49MN/A-2.2110Short Interest ↓ACOGAlpha Cognition2.6108 of 5 stars$9.55+7.3%$20.00+109.4%N/A$154.34M$4.59M-5.97N/APositive NewsCABACabaletta Bio3.0692 of 5 stars$1.68-1.2%$14.50+763.1%-53.5%$153.65MN/A-0.6250Positive NewsCLLSCellectis3.3838 of 5 stars$2.74+2.2%$4.00+46.0%+32.9%$152.29M$49.22M-3.34290Positive NewsShort Interest ↓Gap UpGLSIGreenwich LifeSciences1.5411 of 5 stars$11.17+2.2%$42.00+276.0%-21.8%$152.25MN/A-8.213 Related Companies and Tools Related Companies Climb Bio Competitors Actuate Therapeutics Competitors Nuvectis Pharma Competitors Coherus Oncology Competitors Scilex Competitors Eledon Pharmaceuticals Competitors Alpha Cognition Competitors Cabaletta Bio Competitors Cellectis Competitors Greenwich LifeSciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
